Media center

Contact our media team
Arizona PIRG Education Fund

Are you a member of the media?

Join our media list

This field is for validation purposes and should be left unchanged.
SCOTUS action will limit generic drug competition

Health care

SCOTUS action will limit generic drug competition

U.S. Supreme Court on Monday declined to review a federal circuit court decision that imperils a critical method that many generic drug makers use to win approval. The court denied a petition of certiorari in Teva Pharmaceuticals USA, Inc. V GlaxoSmithKline LLC, Et. Al., allowing the divided lower court's decision to stand. This action can have dramatically limit competition from lower-priced generic and biosimilar medicines.

Media Statements  

Show More